

## MARKETING APPROVAL GRANTED FOR ESTRADIOL SPRAY IN SOUTH AFRICA

Acrux (ASX: ACR) announced today that the Medicines Control Council, the South African agency for therapeutic products, has granted a marketing authorisation in South Africa for ESTRAMIST™, Acrux's estradiol spray for treating menopause symptoms that has been licensed exclusively to Aspen South Africa.

ESTRAMIST is currently marketed in the United States as Evamist®, with marketing applications under review by regulatory authorities in South Korea and additional European territories.

“We are pleased that our marketing partner in South Africa has achieved approval for our estradiol product. We look forward to announcing the product launch and receipt of royalties in due course.” said Acrux Executive Chairman Ross Dobinson.

### Contact

Ross Dobinson, Executive Chairman: 03 9691 5920

### About Acrux (ASX: ACR)

[www.acrux.com.au](http://www.acrux.com.au)

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposits drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.